drugset / Trial / NCT01803152

Dendritic Cell Vaccine for Children and Adults With Sarcoma

NCT01803152

Phase 1 Completed 19 enrolled Macarena De La Fuente, MD
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose if this study is to evaluate an investigational vaccine using patient-derived dendritic cells (DC), a type of white blood cell that helps fight infections in the body, (DC) (a vaccine made out of participants' own cells and tumor) to treat sarcoma.

Timeline

Start
2014-01-06
Primary completion
2019-09-10
Completion
2024-06-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Dendritic Cells Vaccine Vaccine Intravenous
Comparator Gemcitabine Small molecule 1000 mg/m2 Intravenous
Subject Tumor Lysate Unknown 1.5 mg Intravenous
Background Imiquimod Other / unclassified Topical